BioSante Added to NASDAQ Biotechnology Index; Regeneron rises on FDA approval Print E-mail
By Staff and Wire Reports   
Monday, 21 November 2011 19:37
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 7, 2011.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
announced it has been added to the NASDAQ Biotechnology Index® (Symbol: NBI), effective prior to the stock market open today, November 21, 2011.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market capitalization-weighted index, and the index securities are evaluated semi-annually in May and November.

---

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) -0.36% were up 10% Monday after the U.S. Food and Drug Administration approved the company's Eylea drug, used to treat blindness in elderly patients.


Also Monday:


Abiomed, Inc. (NASDAQ: ABMD)
, a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, 2011 at 1:00 p.m. ET.

Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN)
, a developer of innovative disease-modifying medicines for serious illnesses, and the Human Therapeutics Division of Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector® platform and RheoSwitch Therapeutic System® for the treatment of pulmonary arterial hypertension (PAH).

AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging in vitro diagnostic company, recently completed its 2011 pilot study of AppyScore™, a novel blood-based test being developed to assist emergency department physicians manage children and adolescent patients suspected of having acute appendicitis.

EPIC Corporation (PINKSHEETS: EPOR) (the "Company"), announced its plan for the next 12 months, reaffirmed its stock dividend, and shareholders and prospective investors can download the Company's Statement of Information & Annual Report as of September 30, 2011, which includes Financial Statements for the years ending September 30, 2011and 2010, from the Company's website. www.epiccor.com

Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of an investigator-sponsored trial (IST) of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.

GE Healthcare, the healthcare business of GE (NYSE:GE) and Neste Jacobs Oy, a leading global expert in plasma fractionation plant engineering design and construction, announced today that the companies have formed a strategic alliance to assist countries worldwide to become self-sufficient in the manufacture of blood plasma products.

Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc. (Nasdaq:VRUS) announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.

ICON plc, (NASDAQ: ICLR)
; ISIN:IE0005711209, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals ( 600535, SH)for the company’s global Phase III T89 trial.

Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN®, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.

OPTIMIZERx Corp (OTCBB: OPRX) announced continued rapid expansion of its SampleMD eCoupon and Patient Educational support system within leading ePrescribing platforms involving more than 200 Electronic Health Record systems.

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of a global survey conducted during its webinar entitled "Medical Imaging Web Reporting: Helping Sponsors Simplify Central Imaging Study Management through Metrics."

Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA). Validation means that the EMA has confirmed that the application is complete and the agency is beginning its review procedure.

ShangPharma Corporation (NYSE: SHP), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the quarter ended September 30, 2011.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), will be presenting at the 15th Annual Biotech and Specialty Pharmaceuticals Conference on November 30, 2011 at 2:10 p.m. EST.

Viral Genetics (Pink Sheets: VRAL) reports that a patent under which it is exclusively licensed will be granted for using a compound known as DCA to treat cancer.

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today the publication of a darinaparsin (Zinapar® or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science.\



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter